- Home
- QGEN vs VRNA Comparison
QGEN vs VRNA Comparison
Compare QGEN & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QGEN
- VRNA
- Stock Information
- Founded
- QGEN 1986
- VRNA 2005
- Country
- QGEN Netherlands
- VRNA United Kingdom
- Employees
- QGEN N/A
- VRNA N/A
- Industry
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- QGEN Health Care
- VRNA Health Care
- Exchange
- QGEN Nasdaq
- VRNA Nasdaq
- Market Cap
- QGEN 9.1B
- VRNA 8.3B
- IPO Year
- QGEN 1996
- VRNA 2017
- Fundamental
- Price
- QGEN $48.36
- VRNA $104.90
- Analyst Decision
- QGEN Buy
- VRNA Buy
- Analyst Count
- QGEN 8
- VRNA 11
- Target Price
- QGEN $50.68
- VRNA $114.10
- AVG Volume (30 Days)
- QGEN 1.4M
- VRNA 7.2M
- Earning Date
- QGEN 08-05-2025
- VRNA 08-07-2025
- Dividend Yield
- QGEN 3.13%
- VRNA N/A
- EPS Growth
- QGEN N/A
- VRNA N/A
- EPS
- QGEN 0.42
- VRNA N/A
- Revenue
- QGEN $2,002,874,000.00
- VRNA $118,535,000.00
- Revenue This Year
- QGEN $6.36
- VRNA $893.95
- Revenue Next Year
- QGEN $5.70
- VRNA $73.76
- P/E Ratio
- QGEN $114.72
- VRNA N/A
- Revenue Growth
- QGEN 3.31
- VRNA N/A
- 52 Week Low
- QGEN $37.63
- VRNA $18.51
- 52 Week High
- QGEN $48.90
- VRNA $105.30
- Technical
- Relative Strength Index (RSI)
- QGEN 60.00
- VRNA 70.69
- Support Level
- QGEN $47.38
- VRNA $104.58
- Resistance Level
- QGEN $48.47
- VRNA $104.91
- Average True Range (ATR)
- QGEN 0.79
- VRNA 1.88
- MACD
- QGEN -0.13
- VRNA 0.35
- Stochastic Oscillator
- QGEN 66.97
- VRNA 97.86
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.